hrp0084fc7.3 | Growth-promoting therapies | ESPE2015

IGF1 Levels, Complex Formation, and IGF-Bioactivity in GH-Treated Children with Prader–Willi Syndrome

Bakker Nienke , van Doorn Jaap , Renes Judith , Donker Truus , Hokken-Koelega Anita

Background: Children with Prader–Willi syndrome (PWS) attain high serum immunoreactive IGF1 levels during standard dose GH treatment, which leads to concern, but lowering the dose, deteriorates their body composition.Objective and hypotheses: To evaluate serum IGF1, IGFBP3 and acid-labile subunit (ALS) levels, complex formation and IGF-bioactivity in GH-treated PWS children. We hypothesized that GH-treated children with PWS have a normal IGF-bioacti...